BioSyent Inc. (CVE:RX - Get Free Report)'s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$11.29 and traded as low as C$10.96. BioSyent shares last traded at C$11.00, with a volume of 1,550 shares changing hands.
BioSyent Stock Performance
The firm has a market cap of C$128.65 million, a price-to-earnings ratio of 18.50 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The firm has a fifty day simple moving average of C$11.27 and a two-hundred day simple moving average of C$10.94.
Insider Transactions at BioSyent
In other BioSyent news, insider FAX Capital Corp. sold 230,800 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. Also, Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total value of C$55,628.75. Insiders sold a total of 349,144 shares of company stock valued at $3,903,370 in the last three months. 33.65% of the stock is currently owned by company insiders.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
See Also
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
